Unblinded: Rebekah Gee's drug pricing experiment in Louisiana

Louisiana's health secretary negotiated a new payment model with Gilead for one of the poorest states in the country. Could it spread nationwide?

By Andrew Dunn • Aug. 28, 2019

Multiple sclerosis drug costs skyrocketed for Medicare and patients, study finds

Out-of-pocket spending on MS medications increased by more than 600% in the decade from 2006 to 2016, while the typical list price quadrupled.

By Andrew Dunn • Aug. 27, 2019

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Pharmacogenetic test makers cheer UnitedHealth coverage. Other payers aren't there yet.

"I've been concerned that the hype around pharmacogenetics, at least for depression, has gotten out ahead of the data," said one psychiatry expert at Johns Hopkins.

By Graison Dangor • Aug. 27, 2019

Lilly's case for Taltz helped by expanded approval

By prescription numbers, Taltz trails Novartis' rival drug Cosentyx. An approval for use in ankylosing spondylitis will go some ways to level the playing field.

By Ned Pagliarulo • Aug. 26, 2019

Today's data linkage is tomorrow's privacy breach

Is your company at risk?

By Crossix Solutions • Aug. 22, 2019

Trump administration not giving up on plan to require prices in TV drug ads

Amgen, Merck and Eli Lilly successfully blocked the rule from taking effect in July, winning a district court decision that HHS is now appealing. 

By Ned Pagliarulo • Aug. 21, 2019

NHS coverage opens up Hemlibra to thousands more patients

The decision could help Roche's hemophilia drug make headway in the European market, especially among patients without inhibitors.

By Jacob Bell • Aug. 21, 2019

Amgen biosimilar debut boosted by UnitedHealthcare coverage switch

Recently launched Mvasi and Kanjinti, copycat versions of Avastin and Herceptin respectively, will be preferred products for the insurer starting October 1. 

By Ned Pagliarulo • Updated Aug. 19, 2019

Nonprofit under pressure to make new TB drug affordable

Doctors Without Borders is calling on the TB Alliance to set a low price for the drug, and to put money from a sale of a regulatory fast pass toward patient access.

By Jacob Bell • Aug. 15, 2019

Gilead's Descovy set for PrEP approval, but not without data, access concerns

An expert panel recommended the FDA extend approval of Gilead's drug for preventive use, though advisers pushed for further study in cisgender women.

By Jacob Bell • Aug. 8, 2019

Regulators, Gilead at odds over HIV drug's use in women

An expert panel today will discuss Gilead's application for Descovy's use as a preventive treatment for HIV.

By Jacob Bell • Aug. 5, 2019

Congress is going after drug prices. Pharma CEOs aren't panicking, yet

A Senate Finance bill could emerge as the most palatable option for an industry seeking to limit losses in an election cycle already targeting pricing as an issue.

By Ned Pagliarulo • Aug. 2, 2019

White House backs importing drugs from abroad

The Trump administration's latest drug price plan features ideas Republicans traditionally oppose and breaks with past claims about the FDA's ability to safely oversee importation.

By Jonathan Gardner • July 31, 2019

Does your brand need behavioral science?

Does your brand need a behavioral science solution? Find the right solution to meet your needs.

By Meredith Terry, PhD Lead Behaviorist, Innovation and Practice MicroMass Communications, Inc. • July 31, 2019

Sales gap grows between rival Merck, Bristol cancer therapies

Keytruda posted $2.6 billion in sales during the second quarter, spurring Merck to substantially boost its revenue projections for the year.

By Ned Pagliarulo • July 30, 2019

FTC probing J&J on Remicade, as biosimilar market remains muted

The anti-inflammation drug has held onto its market share despite years of biosimilar competition. Now, the FTC wants to know how.

By Andrew Dunn • July 30, 2019

European regulators back Bayer, GW drugs, but with caveats

The CHMP recommended conditional approval of Vitrakvi while also advising Epidiolex be used as adjunctive therapy, an opinion one analyst described as "disappointing."

By Jacob Bell • July 26, 2019

FDA warns cannabis company for illegal marketing of CBD products

At issue are "unsubstantiated claims" made by Curaleaf about the health benefit of its cannabidiol products. 

By Kristin Jensen • July 24, 2019

Advocacy group pledges six-figure ad buy to support Trump drug price plan

Patients for Affordable Drugs relaunched a campaign which supports the Trump administration's proposed International Pricing Index for certain drugs.

By Jonathan Gardner • July 17, 2019

Weathering the privacy storm

How to stay above water in the changing digital marketing landscape.

July 16, 2019

Xarelto falls into the donut hole

A 19% decline from 2018 sales was a dark cloud in an otherwise mostly positive quarterly earnings for Johnson & Johnson.

By Jonathan Gardner • July 16, 2019

ICER unconvinced peanut allergy drugs are better than just avoiding the food

The influential cost watchdog group argues that treatments from DBV and Aimmune haven't shown long-term benefits — or, more broadly, quality-of-life improvements.

By Jacob Bell • July 11, 2019

Billion-dollar settlement gets Reckitt out of federal opioid probes

Company spinout Indivior, however, is still facing criminal charges related to marketing of Suboxone film, an opioid dependence treatment. 

By Jonathan Gardner • July 11, 2019

New GSK data raises threat to Gilead's star HIV drug

Dovato, GSK's two-drug HIV treatment, maintained viral suppression about as well as three-drug regimens with a similar makeup to Gilead's Biktarvy.

By Jacob Bell • July 10, 2019

In win for pharma, Trump TV drug price rule struck down

The federal district court sided with drugmakers, which argued the government overstepped its authority in forcing price transparency in advertisements.

By Jonathan Gardner • July 9, 2019